Literature DB >> 27501913

Occupying a flat subpocket in a tRNA-modifying enzyme with ordered or disordered side chains: Favorable or unfavorable for binding?

Manuel Neeb1, Christoph Hohn2, Frederik Rainer Ehrmann1, Adrian Härtsch2, Andreas Heine1, François Diederich2, Gerhard Klebe3.   

Abstract

Small-molecule ligands binding with partial disorder or enhanced residual mobility are usually assumed as unfavorable with respect to their binding properties. Considering thermodynamics, disorder or residual mobility is entropically favorable and contributes to the Gibbs energy of binding. In the present study, we analyzed a series of congeneric ligands inhibiting the tRNA-modifying enzyme TGT. Attached to the parent lin-benzoguanine scaffold, substituents in position 2 accommodate in a flat solvent-exposed pocket and exhibit varying degree of residual mobility. This is indicated in the crystal structures by enhanced B-factors, reduced occupancies, or distributions over split conformers. MD simulations of the complexes suggest an even larger scatter over several conformational families. Introduction of a terminal acidic group fixes the substituent by a salt-bridge to an Arg residue. Overall, all substituted derivatives show the same affinity underpinning that neither order nor disorder is a determinant factor for binding affinity. The additional salt bridge remains strongly solvent-exposed and thus does not contribute to affinity. MD suggests temporary fluctuation of this contact.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Crystallography; Drug design; Flat-binding pockets; Order-disorder phenomena; Protein–ligand complexes; Residual mobility

Mesh:

Substances:

Year:  2016        PMID: 27501913     DOI: 10.1016/j.bmc.2016.07.053

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  1 in total

1.  Application of ITC-Based Characterization of Thermodynamic and Kinetic Association of Ligands With Proteins in Drug Design.

Authors:  Haixia Su; Yechun Xu
Journal:  Front Pharmacol       Date:  2018-10-11       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.